Recurrence and progression in non-muscle-invasive bladder cancer using EORTC risk tables
It was the aim of this study to evaluate the recurrence and progression at 1, 3 and 5 years in patients with non-muscle-invasive bladder cancer (NMIBC) who underwent a transurethral resection of bladder cancer following intravesical adjuvant chemotherapy or immunotherapy if indicated and to compare...
Uloženo v:
| Vydáno v: | Urologia internationalis Ročník 89; číslo 1; s. 61 |
|---|---|
| Hlavní autoři: | , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
Switzerland
01.01.2012
|
| Témata: | |
| ISSN: | 1423-0399, 1423-0399 |
| On-line přístup: | Zjistit podrobnosti o přístupu |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | It was the aim of this study to evaluate the recurrence and progression at 1, 3 and 5 years in patients with non-muscle-invasive bladder cancer (NMIBC) who underwent a transurethral resection of bladder cancer following intravesical adjuvant chemotherapy or immunotherapy if indicated and to compare them with the European Organization for Research and Treatment of Cancer (EORTC) risk tables.
Between 2002 and 2011, a total of 259 patients with NMIBC were treated with transurethral resection of bladder cancer. According to the clinical and pathological factors used by the EORTC scoring system, the patients were divided into four groups, and for each group, the probabilities of recurrence and progression were calculated.
The recurrence and progression rates of NMIBC of our patients were similar to those in the EORTC risk score system. Moreover, in our sample group, we found a minimally significant reduction in the recurrence rate in the intermediate- and high-risk groups.
From the results obtained, we considered it essential to introduce the use of EORTC risk tables into our clinical practice to determine the recurrence and progression of NMIBC. |
|---|---|
| AbstractList | It was the aim of this study to evaluate the recurrence and progression at 1, 3 and 5 years in patients with non-muscle-invasive bladder cancer (NMIBC) who underwent a transurethral resection of bladder cancer following intravesical adjuvant chemotherapy or immunotherapy if indicated and to compare them with the European Organization for Research and Treatment of Cancer (EORTC) risk tables.OBJECTIVESIt was the aim of this study to evaluate the recurrence and progression at 1, 3 and 5 years in patients with non-muscle-invasive bladder cancer (NMIBC) who underwent a transurethral resection of bladder cancer following intravesical adjuvant chemotherapy or immunotherapy if indicated and to compare them with the European Organization for Research and Treatment of Cancer (EORTC) risk tables.Between 2002 and 2011, a total of 259 patients with NMIBC were treated with transurethral resection of bladder cancer. According to the clinical and pathological factors used by the EORTC scoring system, the patients were divided into four groups, and for each group, the probabilities of recurrence and progression were calculated.PATIENTS AND METHODSBetween 2002 and 2011, a total of 259 patients with NMIBC were treated with transurethral resection of bladder cancer. According to the clinical and pathological factors used by the EORTC scoring system, the patients were divided into four groups, and for each group, the probabilities of recurrence and progression were calculated.The recurrence and progression rates of NMIBC of our patients were similar to those in the EORTC risk score system. Moreover, in our sample group, we found a minimally significant reduction in the recurrence rate in the intermediate- and high-risk groups.RESULTSThe recurrence and progression rates of NMIBC of our patients were similar to those in the EORTC risk score system. Moreover, in our sample group, we found a minimally significant reduction in the recurrence rate in the intermediate- and high-risk groups.From the results obtained, we considered it essential to introduce the use of EORTC risk tables into our clinical practice to determine the recurrence and progression of NMIBC.CONCLUSIONFrom the results obtained, we considered it essential to introduce the use of EORTC risk tables into our clinical practice to determine the recurrence and progression of NMIBC. It was the aim of this study to evaluate the recurrence and progression at 1, 3 and 5 years in patients with non-muscle-invasive bladder cancer (NMIBC) who underwent a transurethral resection of bladder cancer following intravesical adjuvant chemotherapy or immunotherapy if indicated and to compare them with the European Organization for Research and Treatment of Cancer (EORTC) risk tables. Between 2002 and 2011, a total of 259 patients with NMIBC were treated with transurethral resection of bladder cancer. According to the clinical and pathological factors used by the EORTC scoring system, the patients were divided into four groups, and for each group, the probabilities of recurrence and progression were calculated. The recurrence and progression rates of NMIBC of our patients were similar to those in the EORTC risk score system. Moreover, in our sample group, we found a minimally significant reduction in the recurrence rate in the intermediate- and high-risk groups. From the results obtained, we considered it essential to introduce the use of EORTC risk tables into our clinical practice to determine the recurrence and progression of NMIBC. |
| Author | Altieri, Vincenzo Maria Criniti, Pasquale Ricciardulli, Stefano Verratti, Vittore Manco, Rossella Palumbo, Pietro Castellucci, Roberto Olivieri, Raffaella Nicolai, Michele Tenaglia, Raffaele Lanfranco Sut, Michal |
| Author_xml | – sequence: 1 givenname: Vincenzo Maria surname: Altieri fullname: Altieri, Vincenzo Maria organization: Department of Urology, Chair and School of Urology, University of Chieti, Chieti, Italy. vmaltieri @ alice.it – sequence: 2 givenname: Roberto surname: Castellucci fullname: Castellucci, Roberto – sequence: 3 givenname: Pietro surname: Palumbo fullname: Palumbo, Pietro – sequence: 4 givenname: Vittore surname: Verratti fullname: Verratti, Vittore – sequence: 5 givenname: Michal surname: Sut fullname: Sut, Michal – sequence: 6 givenname: Raffaella surname: Olivieri fullname: Olivieri, Raffaella – sequence: 7 givenname: Rossella surname: Manco fullname: Manco, Rossella – sequence: 8 givenname: Stefano surname: Ricciardulli fullname: Ricciardulli, Stefano – sequence: 9 givenname: Michele surname: Nicolai fullname: Nicolai, Michele – sequence: 10 givenname: Pasquale surname: Criniti fullname: Criniti, Pasquale – sequence: 11 givenname: Raffaele Lanfranco surname: Tenaglia fullname: Tenaglia, Raffaele Lanfranco |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/22722366$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkEtLAzEUhYNU7EMX_gHJ0s1oHpOkWUppVSgUSgV3Q5K5U6IzmZp0Cv57A1aQuzh38Z17D2eKRqEPgNAtJQ-UCv1ICOFcCiov0ISWjBeEaz36t4_RNKUPQjKs1RUaM6YY41JO0PsW3BAjBAfYhBofYr-PkJLvA_YB50dFNyTXQuHDySR_AmxbU9cQsTPZFPGQfNjj5Wa7W-Do0yc-GttCukaXjWkT3Jx1ht5Wy93ipVhvnl8XT-vCccWOBZNEAIBoLBdNI3NWLTTjc6cMLzlx9Xxe2tpIoVxDDNO6UaWm0jqqGmEJZzN0_3s3J_8aIB2rzicHbWsC9EOqKOFE5OEko3dndLAd1NUh-s7E7-qvDfYDjNphSA |
| CitedBy_id | crossref_primary_10_1016_j_ebiom_2016_08_051 crossref_primary_10_1111_iju_15263 crossref_primary_10_1159_000368166 crossref_primary_10_1097_PAP_0000000000000050 crossref_primary_10_1111_iju_12572 crossref_primary_10_1111_bju_12495 crossref_primary_10_1159_000351036 crossref_primary_10_1016_j_euf_2018_11_005 crossref_primary_10_1016_j_ucl_2019_09_003 crossref_primary_10_1016_j_clgc_2015_09_005 crossref_primary_10_1111_iju_12509 crossref_primary_10_1016_j_path_2015_07_003 crossref_primary_10_1159_000355358 crossref_primary_10_1159_000355467 crossref_primary_10_1159_000350232 crossref_primary_10_1007_s00120_018_0641_3 crossref_primary_10_1016_j_semcancer_2013_02_002 |
| ContentType | Journal Article |
| Copyright | Copyright © 2012 S. Karger AG, Basel. |
| Copyright_xml | – notice: Copyright © 2012 S. Karger AG, Basel. |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1159/000336516 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1423-0399 |
| ExternalDocumentID | 22722366 |
| Genre | Journal Article |
| GeographicLocations | Italy |
| GeographicLocations_xml | – name: Italy |
| GroupedDBID | --- .GJ 0R~ 0~5 0~B 123 30W 329 34G 36B 39C 3O- 3O. 4.4 53G 5RE 8UI AALGM AAYIC ABBTS ABJNI ABPAZ ABWCG ACGFS ACPSR ACQXL ADAGL ADBBV AENEX AEYAO AFJJK AFSIO AHFRZ ALDHI ALMA_UNASSIGNED_HOLDINGS AZPMC CAG CGR COF CS3 CUY CVF CYUIP DU5 E0A EBS ECM EIF EJD EMB EMOBN F5P FB. HZ~ IAO IHR ITC IY7 KUZGX N9A NPM O1H O9- RIG RKO RXVBD SV3 UJ6 X7J ZGI ZXP 7X8 |
| ID | FETCH-LOGICAL-c372t-2605eee5fb35ff6399959238c7a3430cd884bda657cf0a299f74916bc17f5b032 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 21 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000306888100010&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1423-0399 |
| IngestDate | Fri Jul 11 08:59:35 EDT 2025 Wed Feb 19 02:04:33 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| License | Copyright © 2012 S. Karger AG, Basel. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c372t-2605eee5fb35ff6399959238c7a3430cd884bda657cf0a299f74916bc17f5b032 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| PMID | 22722366 |
| PQID | 1030505030 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_1030505030 pubmed_primary_22722366 |
| PublicationCentury | 2000 |
| PublicationDate | 2012-01-01 |
| PublicationDateYYYYMMDD | 2012-01-01 |
| PublicationDate_xml | – month: 01 year: 2012 text: 2012-01-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | Switzerland |
| PublicationPlace_xml | – name: Switzerland |
| PublicationTitle | Urologia internationalis |
| PublicationTitleAlternate | Urol Int |
| PublicationYear | 2012 |
| SSID | ssj0015997 |
| Score | 2.0321224 |
| Snippet | It was the aim of this study to evaluate the recurrence and progression at 1, 3 and 5 years in patients with non-muscle-invasive bladder cancer (NMIBC) who... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 61 |
| SubjectTerms | Adult Aged Aged, 80 and over Chemotherapy, Adjuvant Chi-Square Distribution Cystectomy - adverse effects Disease Progression Female Humans Immunotherapy Italy Male Middle Aged Multivariate Analysis Neoplasm Grading Neoplasm Invasiveness Neoplasm Recurrence, Local Neoplasm Staging Neoplasms, Multiple Primary Risk Assessment Risk Factors Time Factors Treatment Outcome Tumor Burden Urinary Bladder Neoplasms - immunology Urinary Bladder Neoplasms - pathology Urinary Bladder Neoplasms - surgery |
| Title | Recurrence and progression in non-muscle-invasive bladder cancer using EORTC risk tables |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/22722366 https://www.proquest.com/docview/1030505030 |
| Volume | 89 |
| WOSCitedRecordID | wos000306888100010&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1JS8NAFB7UinhxX-rGCF4Hk8yWnERKi5fWUirkVjKTGSloWpu2v9_3khRPguAlh4SB4fHNmy9v-wh5iCNAAReGRdI7JkTgmMlcwjwPQxtbkXgjKrEJPRjEaZoMm4Bb2ZRVbnxi5ajzmcUY-SPKYUkcXhI8zb8YqkZhdrWR0NgmLQ5UBlGt058sgkxqcRWgDCyAz81kIXiPDQycKxmq35lldcP0Dv-7tyNy0HBL-lyD4ZhsueKE7PWb7PkpSUcYXK_a-2hW5LSqzarnctBpQYtZwT5XJSxl02KdYV07NR_omRbUIjgWFKvk32n3dTTuUCxKp0vsvCrPyFuvO-68sEZZgVmuoyXDnxjnnPSGS--RpCQSmF5sdcYFD2wex8LkmZLa-iCDG8trATzS2FB7aQIenZMd2JS7JFSCO5WaA3MCahYaldhM5VqoWOexh-PdJvcbm00AuZiOyAo3W5WTH6u1yUVt-Mm8HrExiSINvEWpqz-svib7QGqiOi5yQ1oezq27Jbt2vZyWi7sKEvAcDPvfoLa_JQ |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Recurrence+and+progression+in+non-muscle-invasive+bladder+cancer+using+EORTC+risk+tables&rft.jtitle=Urologia+internationalis&rft.au=Altieri%2C+Vincenzo+Maria&rft.au=Castellucci%2C+Roberto&rft.au=Palumbo%2C+Pietro&rft.au=Verratti%2C+Vittore&rft.date=2012-01-01&rft.eissn=1423-0399&rft.volume=89&rft.issue=1&rft.spage=61&rft_id=info:doi/10.1159%2F000336516&rft_id=info%3Apmid%2F22722366&rft_id=info%3Apmid%2F22722366&rft.externalDocID=22722366 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1423-0399&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1423-0399&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1423-0399&client=summon |